Travere Therapeutics, Inc. Common Stock — gráfico, cotizaciones y noticias (NASDAQ:TVTX) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Market Capitalization 2.8318 B
Employee 497
Founded 2011
CEO N/A
Website www.travere.com
Headquarter California, United States
FIGI BBG000P9D6W9
Industry Technology

Ingresos totales

Beneficio neto

Beneficio básico por acción

Deuda total

Flujo de caja libre

Efectivo y equivalentes

2.83 B Capitalización de mercado

Ratio precio/beneficio

-131.76

Relación precio/flujo de caja

6.95

Noticias

Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript

Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS - Slideshow (NASDAQ:TVTX) 2026-04-13

Cipher Mining Stock, Five Below, Indivior Among 10 New Stocks On IBD Watchlists

La FDA aprueba Filspari para FSGS, segunda indicación de Travere

ASML, An AI Megatrend Star, Leads 8 Newcomers To Best Stock Lists

Baynes Roy D. vende acciones de Travere Therapeutics (TVTX) por 330.000 dólares

Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma

IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out

VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study

Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX)